Scott: Breast Cancer Genetics Flashcards

1
Q

where does breast cancer arise from within normal tissue?

A

epithelial layer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

T or F: adult tissue contains stem and progenitor cells which provided capacity for growth throughout the lifespan?

A

true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

_____ mutation affects all cells in the body

A

germline mutations (err or sperm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

____ mutation occurs in a cell in the body, only affects a single cell and its clonal descendants

A

somatic mutation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

is a somatic mutation passed down through life of the individual and onto its offspring?

A

NO. not to offspring, NOT a germline mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

inheritance of susceptibility (BRCA 1 and 2) is what type of inheritance pattern?

A

Autosomal dominant. inheritance of a single copy confers susceptibility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what does BRCA1 and 2 actually DO?

A

essential components of homologous recombination arm of DNA repair machinery, which then allows for genomic instability creating conditions for oncogenic somatic mutations to arise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

in the _____ (absence or presence) of BRCA1, luminal progenitor cells accumulate

A

absence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what percentage of breast cancers are sporadic?

A

90%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

subtypes differ in clinical characteristics: Luminal A has _____ (low, normal, high) levels of estrogen receptor, and therefore a _____ (worst, unchanging, best) prognosis?

A

HIGH. BEST.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

subtypes differ in clinical characteristics: _____ is the overexpression of HER2 and the prognosis is improved with ______

A

HER2-amplified. Trastuzamab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

subtypes differ in clinical characteristics: what type is often triple negative (NO ER, PR, no amp of HER2), BRCA mutations

A

BASAL-like

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what treatments are used to block ER signaling in treating ER+ breast cancer?

A

Selective estrogen receptor modulators, aromatase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

ERalpha promotes transcription of secreted growth factor, such as _____

A

amphiregulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

extracellular estrogen controls proliferation of luminal cells _____ (direct/indirect)

A

INDIRECtly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

tumor cells estrogen regulates growth _____ (direct/indirectly)

A

directly

17
Q

How are tumor cells different than normal cells?

A

increase in # of cells expressing ER. change in which genes are regulated by ER binding

18
Q

how are tumor cells NOT different than normal cells?

A

no mutations or amplifications of genes encoding estrogen or RE

19
Q

how does ER promote transcription of a different set of genes in breast cancer?

A

overexpression of the pioneer transcription factor FOXA1

20
Q

how does FOXA1 work?

A

it allows BINDING OF CLOSED chromatin at select sites and opens it and allows access to ER binding!!!!

21
Q

what is one of the sites opened by FOXA1?

A

CYCLIN D1 promoter (therefore dysregulates proliferation)

22
Q

what was the first SERM used to block E2/Er signaling in breast cancer?

A

Tamoxifen

23
Q

________ type of drugs block synthesis of estrogen in non-ovarian tissues

A

Aromatase inhibitors. they DO NOT AFFECT THE ESTROGEN RECEPTOR

24
Q

T or F: ERBB2 does require ligand binding for activation

A

FALSE. DOES NOT. increased ERBB2 expression, due to amplification allows dimerization to occur by mass action.

25
Q

____ is a monoclonal antibody that binds extracellular domain of ERBB2 and blocks activity of its homodimers

A

Trastuzumab

26
Q

____ is a small molecule inhibitor which binds and blocks kinase active site and blocks the EGFR-ERBB2 heterodimer activity

A

lapatinib